blindness with semaglutide Popular Weight Loss Drugs Linked To Rare Cases Of Permanent | 10 News+ semaglutide causing blindness A new

[PubMed: 20122450] 71

Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, et al

PTEN loss and VEGF overexpression are closely correlated in breast cancer

Compounded semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist which may be used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m^2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)

A sudden change in the amount of body fat, as seen from bariatric surgery and sometimes from GLP-1 medications, may signal to the brain that it is not a safe time to reproduce and limit fertility, he added

Kubala, M